ALB and early-onset autosomal dominant Alzheimer disease: As investigated in Alzheimer’s disease [31–33], PE with albumin replacement (PE-A) may alter the metabolic profile of the plasma and cerebrospinal fluid in ALS patients by removing disease-inducing molecules and providing benefits related to the multiple functions of albumin.